Since its foundation in 2008, AMW has developed an attractive and advanced product pipeline: 4 products are currently filed for approval (launch expected in 2013/14) and 4 further products are in progressed clinical development. AMW`s manufacturing site in Warngau, Germany, is GMP approved, including approval in accordance of the controlled substances act.
Prior to the foundation of AMW GmbH, Dr. Fischer had founded his first company, Novosis AG in 1997. After a successful sale of the company to the Swiss Schweizerhall Group, the company now operates under the name of Acino AG. The core area of both companies was, from the start, development and production of new and technologically demanding drug delivery systems. Thus Dr. Fischer could grow the Acino AG to one of the largest contract manufacturers of generic transdermal systems in Europe.
AMW GmbH had developed beyond that. The business model of AMW is built on two pillars: proprietary products and development and supply contracts with pharmaceutical and MedTech companies. Proprietary products: AMW carries out clinical development through the approval process at its own or at shared costs and thus owns or at least co-owns IP and marketing rights. The approved products are licensed out to a marketing partner. We provide our development partners comprehensive services, from initial ideas to the approval and registration of complex products and their production, as well as selected individual services. Excellence in research and development, transparence and reliability in project work as well as precision in manufacturing are our key to success in all partnerships.
The current most important products include diverse highly active implants and transdermal patches, such as for the treatment of certain hormone responding tumors, chronic pain or neurologic and psychiatric diseases. In addition, we have developed new patented technologies for the active control of drug releasing pharmaceuticals as well as innovative approaches for transdermal delivery.